FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPE	ROVAL
OMB Number:	3235-0287
Estimated average	burden
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

ATE DII	(First)	0.6:111.)			2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLEY OAKS ROAD, SUITE 108				3. Date of Earliest Transaction (Month/Day/Year) 02/01/2021								X Officer (give title below) Other (specify below) VP of Research & Development					
(Street) WALTHAM, MA 02452				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person _ Form filed by More than One Reporting Person					
	(State)	(Zip)			Т	able I	- Non-	Deriv	ative S	Securitie	es Acquir	ed, Dispose	d of, or Bene	ficially Own	ed		
(Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)		Date, if	Code (Instr. 8)		(A	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)			Ownership Form:	Beneficial	
					/ i cai)	Code V		V Aı	Amount (A) or (D)		Price	(msu. 3 and	*)		or Indirect (I)	Ownership (Instr. 4)	
tock		02/02/2021				F <u>(1</u>)	98	88	D	6.34	16,268			D		
		Table II -					uired, l	. J Dispo	sed of,	or Bene	eficially (
1. Title of Derivative Conversion Security (Instr. 3) Price of Derivative Security Security Security 3. Transaction Date (Month/Day/Year		any	4. 5. N Transaction of Code Sec ear) (Instr. 8) Acc or I			ber vative ies ed (A) osed	6. Date Expira	Date Exercisable and Expiration Date			7. Title and Amount of Underlying Securities (Instr. 3 and 4)			Derivative Securities Beneficially Owned Following Reported Transaction(s	Owners Form of Derivat Security Direct (or Indirect)	Benefic Owners (Instr. 4 D)	
			Code	V	(A)	(D)	Date Exerci	sable		ation	Title	or		(Instr. 4)	(Instr. 4)	
\$ 6.46	02/01/2021		A		10,000	0	<u>(</u>	3)	02/03	1/2031	Comm	110.00	\$ 0	10,000	D		
tion p	ock overt on a second or a sec	ock ort on a separate line for each sort on a separate line for e	Table II - Table II - Month/Day/Year) 3. Transaction Date (Month/Day/Year) Table II - Month/Day/Year) 3. Transaction Date (Month/Day/Year) Month/Day/Year) 3. Transaction Date (Month/Day/Year) Month/Day/Year)	Table II - Derivate (e.g., pu on the continuity) Table II - Derivate (e.g., pu on the continuity)	Table II - Derivative Security 3. Transaction Date Oct On a separate line for each class of securities beneficially of the Exercise Ce of rivative curity Table II - Derivative Security Security (Month/Day/Year) 3. Transaction Date Execution Date (Month/Day/Year) (Month/Day/Year) 3. Transaction Date Execution Date (Month/Day/Year) (Month/Day/Year) Table II - Derivative Securities beneficially of the Code (Instr. 8) Code V	Table II - Derivative Securities beneficially owned discovered inversion Exercise ce of rivative curity A. Deemed Execution Date, if any (Month/Day/Year)	Table II - Derivative Securities Acq (e.g., puts, calls, warrants. A. Deemed Execution Date, if any (Month/Day/Year)	Table I - Non- Table II - Derivative Securities Securities Deneficially owned directly or indirectly or ind	Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3, 4, and 5) Table I - Non-Derivative Securities Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) Table II - Non-Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) Table II - Code V (A) (D) Table II - Non-Derivative Securities Beneficially owned directly or indirectly. Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3, 4, and 5) Date Exercise Code V (A) (D)	Table I - Non-Derivative Securities Acquired, Disposed of rivative Curity Table II - Derivative Securities Acquired, Disposed of rivative Curity Table II - Derivative Securities Acquired, Disposed of rivative Curity A. Deemed Execution Date, if Code V (Instr. 3) Code V (Instr. 3) Persons who in this form a displays a curity (Month/Day/Year) 3. Transaction Date Exercise (Month/Day/Year) Table II - Derivative Securities Acquired, Disposed of (e.g., puts, calls, warrants, options, convertibent of Derivative Securities Acquired (A) or Disposed of (Derivative Securities Acquired (A) or Disposed of Operivative Securities Acquired (A) or Disposed of (Derivative Securities Acquired (A) or Disposed of Operivative Securities Acquired (A) or Disposed of Operivative Securities Acquired (A) or Disposed of (Derivative	(State) (Zip) Table I - Non-Derivative Securities Acquired (Instr. 3, 4 and 5) Table II - Derivative Securities Securities Securities Securities Page (A) or Disposed of (Instr. 8) Table II - Non-Derivative Securities Acquired (Instr. 3) (A) or Disposed of (Instr. 8) Table II - Derivative Securities Acquired, Disposed of, or Bene (e.g., puts, calls, warrants, options, convertible security (Month/Day/Year) Table II - Derivative Securities Acquired, Disposed of, or Bene (e.g., puts, calls, warrants, options, convertible security (Month/Day/Year) Table II - Derivative Securities Acquired, Disposed of, or Bene (e.g., puts, calls, warrants, options, convertible security (Month/Day/Year) Table II - Derivative Securities Acquired, Disposed of, or Bene (e.g., puts, calls, warrants, options, convertible security (Month/Day/Year) Table II - Derivative Securities Acquired, Disposed of, or Bene (e.g., puts, calls, warrants, options, convertible security (Month/Day/Year) Table II - Derivative Securities Acquired, Disposed of, or Bene (e.g., puts, calls, warrants, options, convertible security (Month/Day/Year) Table II - Derivative Securities Acquired, Disposed of, or Bene (e.g., puts, calls, warrants, options, convertible security (Month/Day/Year) Table II - Derivative Securities Acquired, Disposed of Date (B., puts, calls, pu	Table I - Non-Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) Table II - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3) Table II - Non-Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) Table II - Non-Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) Table II - Derivative Securities Acquired (D) Price Table II - Derivative Securities Acquired (D) Securities (Code (Instr. 8) (Instr. 3)	Table II - Derivative Securities Date Date Code V Amount Code V Amount Code Code	A, MA 02452 State Cap Table I - Non-Derivative Securities Acquired, Disposed of, or Bene Execution Date, if (Month/Day/Year) State Code (Instr. 8) Code (A) or Disposed of (D) (Instr. 3, 4 and 5) (Instr. 3 and 4) (Instr. 3) (Ins	A, MA 02452 State Cap Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned Ce, Eq. puts, calls, warrants, options, convertible securities Acquired (A) or Disposed of (D) Code (Ce, Eq. puts, calls, warrants, options, convertible securities Code (Ce, Eq. puts, calls, warrants, options, convertible securities Code (Ce, Eq. puts, calls, warrants, options, convertible securities Code (Ce, Eq. puts, calls, warrants, options, convertible securities Code (Ce, Eq. puts, calls, warrants, options, convertible securities Code (Ce, Eq. puts, calls, warrants, options, convertible securities Code (Ce, Eq. puts, calls, warrants, options, convertible securities Code (Code (Ce, Eq. puts, calls, warrants, options, convertible Code (Code (Code (Ce, Eq. puts, calls, warrants, options, convertible Code (Code (Code (Code (Code (Ce, Eq. puts, calls, warrants, options, convertible Code (Code (C	(State) (State) (State) (Table I - Non-Derivative Securities Acquired (A) or Disposed of Date (Month/Day/Year) (Month/Day/Yea	

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Mann Brenda C/O EYEGATE PHARMACEUTICALS, INC. 271 WAVERLEY OAKS ROAD, SUITE 108 WALTHAM, MA 02452			VP of Research & Development					

Signatures

/s/ Sarah Romano, Attorney-in-Fact*	02/03/2021
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Sale of shares to cover taxes due on restricted stock that vested on 02/01/2021.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$6.32 to \$6.34, inclusive. The reporting person hereby (2) undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- (3) The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2022, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.

Remarks:

*Signed under power of attorney on behalf of Reporting Person

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.